Navigation Links
Regulus Provides Update on 'Road to the Clinic' Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
Date:5/14/2013

continue to focus our efforts on preparing for a successful transition to a clinical-stage company and remain on track to nominate our second microRNA candidate for clinical development by the end of the year.  Our recent progress is encouraging and we look forward to realizing the potential that our microRNA technology may have in transforming the field of drug discovery."

Neil W. Gibson , Ph.D., Chief Scientific Officer, added, "We believe that RG-101 is a novel, pan-genotypic agent that may play an important role in future HCV therapy. We are very encouraged by the pre-clinical data seen to date, which includes activity against some of the known mutations that lead to resistance to the current HCV therapies and a favorable potency and PK profile which supports a once-a-month dosing paradigm.  We believe that RG-101 may be useful in difficult-to-treat HCV patients in combination with existing and emerging therapies and we look forward to exploring its clinical utility."

Garry E. Menzel , Ph.D., Chief Operating Officer and Executive Vice President of Finance, said, "As we prepare for clinical activity with RG-101, Regulus continues to maintain a strong financial position with over $90 million in cash at quarter-end. We remain on track to achieve our stated goals of finishing 2013 with at least $60 million in cash, while maintaining a burn rate of approximately $30 million to $35 million."

Recent Highlight

  • Selected New Opportunity in Oncology.  Regulus also announced today that it has selected microRNA-221 (miR-221) as an attractive target for potential clinical evaluation in patients with hepatocellular carcinoma (HCC).  Regulus is currently conducting target validation activities and expects to report further progress on this opportunity in the second half of 2013.
  • First Quarter 2013 Financial Results & Highlights Regulus reported a net loss o
    '/>"/>

    SOURCE Regulus Therapeutics Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
    2. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
    3. Regulus to Present at Future Leaders in the Biotech Industry Conference
    4. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
    5. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
    6. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
    7. Regulus to Present at Two Upcoming Investor Conferences
    8. Regulus Appoints Mark G. Foletta to its Board of Directors
    9. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
    10. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
    11. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... Company (NYSE: PRGO ; TASE) today announced ... from the U.S. Food and Drug Administration (FDA) for ... gel 1.0%. FDA concluded that Perrigo,s testosterone product is ... substituted with the full expectation that it will produce ... 1% when used under the conditions specified in the ...
    (Date:7/24/2014)... , July 24, 2014 Research ... "Machine Health Monitoring Market by Product, Component, Application and ... report to their offering. ... market is expected to witness a moderate growth as ... have almost reached the saturation levels. The ...
    (Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- Delivery ... once order is placed. Photo - ... a professional and in-depth market survey on Global ... reviews the basic information of Hemodialysis Machine including ... then explores global and China,s top manufacturers of ...
    Breaking Medicine Technology:Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5
    ... Dec. 8, 2010 Reportlinker.com announces that a ... catalogue: Astellas Pharma Inc.: PharmaVitae ... IntroductionThis analysis examines the historical ... pharmaceutical sector. The profile encompasses global company strategy, ...
    ... 8, 2010 Healthpoint today announced that the U.S. ... commercial supplies of Collagenase SANTYL® Ointment, a biologic enzymatic ... Sterile & Specialty Products facility in Lakewood, New Jersey. ... the brand. "The approval of this second ...
    Cached Medicine Technology:Reportlinker Adds Astellas Pharma Inc.: PharmaVitae Profile 2FDA Approves New Manufacturing Facility for Collagenase SANTYL® Ointment 2
    (Date:7/24/2014)... Doheny HealthDay Reporter THURSDAY, ... often don,t view their kids as unhealthy or recognize the ... new study. The children of the families surveyed for ... Hasbro Children,s Hospital in Providence, R.I. "A third categorized ... researcher Dr. Kyung Rhee, now an assistant professor of pediatrics ...
    (Date:7/24/2014)... have found a way to delay or even prevent ... with the anti-aging protein Klotho can prevent neuron death ... glutamate. These findings currently appear in the Journal ... the most frequent age-related dementia affecting 5.4 million Americans ... and more than 40 percent of people over the ...
    (Date:7/24/2014)... (PRWEB) July 24, 2014 News ... that it has achieved certification for compliance with ... and verified by the DoD Information Assurance Certification ... Neutral Archive, identified within the DoD as the ... to Operate designation from the U.S. Army Medical ...
    (Date:7/24/2014)... positive outcomes experience paradoxical feelings of pleasure and ... of the brain, according to research led by ... Princeton Neuroscience Institute at Princeton University. , ... of more than 300 products using an auction-like ... products with different or similar values and were ...
    (Date:7/24/2014)... 24, 2014 Horizon BCBSNJ’s second annual ... lucky family a rent-free week in a beautiful Lavallette ... 2014. Don’t miss your chance to win a week’s ... to all New Jersey residents, 25 or older.* Residents ... http://www.facebook.com/HorizonBCBSNJ . , “A family vacation at ...
    Breaking Medicine News(10 mins):Health News:Parents of Obese Kids Often View Them as Healthy 2Health News:Parents of Obese Kids Often View Them as Healthy 3Health News:BU researchers discover that Klotho is neuroprotective against Alzheimer's disease 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 4Health News:Brain's dynamic duel underlies win-win choices 2Health News:Brain's dynamic duel underlies win-win choices 3Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2
    ... LDG ) today reported preliminary total retail drug,store sales for the five-week and nine-week periods ended April 3, 2008., , ... Periods ended April 3, 2008, ... Month Quarter to Date (Dollars in millions) ... (9 weeks), Total retail drug store sales $474 ...
    ... IRIDEX,Corporation (Nasdaq: IRIX ) today reported final financial results ... Revenue for the fourth quarter of 2007 was $14.1 ... fourth quarter of 2006. The,Company,s net loss was $15.8 million ... compared with a loss of $3.8 million or $0.48 per,diluted ...
    ... consequences of misuse , , THURSDAY, April 10 (HealthDay News) ... abuse of powerful narcotic painkillers such as Oxycontin or ... testing --- before dispensing the medications to patients, new ... medical staff were also part of the procedures used ...
    ... Pennsylvania School of Medicine have discovered that a protein ... heart muscle protein called actin. Whats more, Lmod directs ... of the heart. The findings appear in this weeks ... Lmod when we began this study, says lead author ...
    ... Methodist Healthcare -- Memphis,Hospitals ("Methodist") announced today that it ... maturities of the,Bonds. The tender offer was extended on ... 9, 2008 at 5:00 pm, New York City time. ... terminated is applicable to,the following: for the Series 1985C ...
    ... Held on Saturday, April 12th at the ... Helen Mills Theatre in NYC, NEW ... performing a benefit concert on Saturday,April 12th at the Helen Mills Theatre ... This One,s Personal: A,Concert to Stop ACD," is being hosted by the ...
    Cached Medicine News:Health News:Longs Reports Preliminary March Retail Drug Store Sales 2Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 7Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 8Health News:User Registry May Help Docs Stem Painkiller Abuse 2Health News:Penn researchers discover 'modus operandi' of heart muscle protein 2Health News:Methodist Healthcare - Memphis Hospitals Announces Termination of Tender Offers 2Health News:Kristin Chenoweth to Perform Benefit Concert for 3 Angels Memorial Fund titled, 'Kristin Chenoweth, This One's Personal: A Concert to Stop ACD' 2Health News:Kristin Chenoweth to Perform Benefit Concert for 3 Angels Memorial Fund titled, 'Kristin Chenoweth, This One's Personal: A Concert to Stop ACD' 3
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: